What cultivated chicken is and how it is made
Cultivated chicken is chicken meat produced from cultured animal cells instead of from a bird raised to slaughter weight. A small sample of cells is taken from a chicken or from an egg, a cell line is established and banked, and the cells are grown in a bioreactor in a medium of nutrients, then harvested as a food ingredient.
The first approved process shows the steps. The Singapore record for Eat Just describes an immortalised chicken cell line, cell growth in a basal medium of amino acids, vitamins and salts supplemented with fetal bovine serum, harvest, concentration by centrifugation, washing and frozen storage at minus 20 degrees Celsius. Purity tests run throughout.
Later processes change the cells and medium. A serum-free version of the same cell line was allowed in 2023. A 2025 approval for Vital Meat covers chicken embryonic stem cells grown in a food-safe medium without animal-derived components, containing sugars, vitamins, amino acids, proteins, minerals, polyamines, vegetable fat and an anti-shearing agent.
The output is a wet cell mass, not a finished cut. Composition resembles muscle only loosely, and most products blend the cells with plant protein, fat and binders to reach the desired texture. For that reason cultivated chicken is best seen as a new ingredient class within hybrid products, not a one-to-one replacement for a chicken breast.
Composition and nutrition
The specification in the Singapore approval gives a clear picture. Cultured chicken cells contain 85 to 95 percent moisture, 5 to 10 percent protein, 0.5 to 2 percent fat, up to 2 percent ash and up to 2 percent carbohydrate. This is a wet, low-solids material that behaves more like a paste than a dry protein powder.
The Vital Meat specification is similar. It requires protein above 6 percent, moisture above 70 percent and pH above 5, with limits for mercury, arsenic, lead, cadmium, tin and antimony, and for Enterobacteriaceae, Bacillus cereus, Clostridium perfringens and Staphylococcus aureus. The metals and microbial limits reflect the aseptic, bioreactor-based nature of the process.
Because the cells are animal cells, the protein is expected to resemble chicken protein in amino acid terms. Detailed amino acid and digestibility data for an approved ingredient sit in the applicant’s dossier, so buyers should request them from the supplier and should not assume equivalence with conventional chicken breast without that evidence.
Micronutrient content depends on the medium and on the cell type. Because the material is a wet cell mass with low solids, values per 100 g are modest and differ from those of conventional chicken muscle. Developers who want to make nutrient claims should analyse the finished food instead of inferring values from the animal product.
Cultivated chicken production challenges
Growth medium is the main cost. A 2026 review states that cultured meat is limited by high production costs and technical difficulties in large-scale bioreactor production, that the price of pure amino acids and growth factors remains a major cost, and that plant-based hydrolysates are being tested as cheaper alternatives. Low growth rates and shear damage are further limits.
Serum is both a cost and an ethical issue. Fetal bovine serum comes from fetuses of slaughtered pregnant cows, and more than two million bovine fetuses are used worldwide to make about 800,000 litres. A review notes it is expensive, hard to replace completely and not verified for repeated ingestion, so serum-free media are a priority.
Scale-up needs scaffolds or structure for whole cuts. Reviews point to scaffold development as a necessary part of cultured meat research, along with microcarriers for expansion. For ingredient-style products, such as nuggets or blends, the cells can be used as a paste, which avoids the harder problem of building thick, structured muscle tissue.
Environmental claims are contested. Early life cycle assessments cited in a review found that cultured meat had the highest impact among the meat alternatives, mostly because of energy needs, lower than beef and possibly pork but higher than chicken and plant proteins. The authors note process innovation could reduce energy use, so results will change.
Approvals of cultivated chicken
Singapore was first. The Singapore Food Agency allowed cultured chicken cells from Eat Just on 26 November 2020, after a review by SFA and an expert working group that found no food safety concerns. A serum-free version followed on 11 January 2023, and cultivated chicken biomass from Vital Meat on 17 October 2025.
The Singapore list also covers other species: cultured Japanese quail fibroblasts from Vow on 22 March 2024, cultured duck from Suprême on 10 April 2026 and cultivated thin-cut steak from Aleph Farms on 22 July 2026. These approvals show that regulators are processing applications product by product, with specifications for each cell line and process.
In the United States, the FDA runs a voluntary pre-market consultation that evaluates the cell line, banking, manufacturing controls and all inputs. It completed its first consultation for a human food made from cultured animal cells on 16 November 2022. The inventory lists chicken cell material files 000001, 000002 and 000039, plus pork fat and salmon.
For poultry, the FDA regulates cell collection, banking, growth and differentiation, and then transfers oversight to USDA-FSIS at harvest through processing and labelling. This split reflects the Poultry Products Inspection Act. In the EU, cultivated meat is a novel food and needs EFSA assessment and a Union list entry, so sales depend on that process.
Uses and sourcing
Early uses are blended products. Cultivated chicken cells suit nuggets, minced products and hybrid plant-based meats, where the cell content is a fraction of the recipe and plant proteins supply structure. Volumes are small and costs are high, so the ingredient is most realistic in premium or limited-run products for now.
Related ingredients include cultivated beef and cultivated fat, which solve other parts of the meat structure problem. Fat in particular is a flavour and texture driver, and cell-based fat can be combined with plant protein. The wider category is covered on the page for cultivated meat in general for developers.
Buyers and partners should ask for the cell line origin and bank, medium composition, serum status, harvest form, protein and moisture specification, contaminant limits, regulatory approvals by market, production scale and price. Because the sector is young, contract terms need to cover supply continuity and the regulatory status for each country where the product will be sold.
Comparison with plant-based chicken
Compared with plant-based chicken, cultivated chicken contains real animal cells and so offers a closer flavour and a complete animal protein profile, but it costs far more and has fewer approvals. Plant-based products are established, whereas cell-based products are limited to niche markets and blended formats until process costs fall.
For developers, the pragmatic path is hybrid: use cultivated cells for flavour and animal-protein identity, and plant protein, fibre and fat for bulk and texture. Claims should reflect the actual cell content, labelling must follow each market’s rules for cell-cultured foods, and sourcing agreements should account for the approval status of the supplier.